Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant IDH1 regulates the tumor-associated immune system in gliomas.

Genes & development - 15 Apr 2017

Amankulor Nduka M, Kim Youngmi, Arora Sonali, Kargl Julia, Szulzewsky Frank, Hanke Mark, Margineantu Daciana H, Rao Aparna, Bolouri Hamid, Delrow Jeff, Hockenbery David, Houghton A McGarry, Holland Eric C

Abstract excerpt

Gliomas harboring mutations in isocitrate dehydrogenase 1/2 (IDH1/2) have the CpG island methylator phenotype (CIMP) and significantly longer patient survival time than wild-type IDH1/2 (wtIDH1/2) tumors. Although there are many factors underlying the differences in survival between these two tumor types, immune-related differences in cell content are potentially important contributors. In order to investigate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotaxis
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune System

Share to Isocitrate Dehydrogenase

Share to Leukocyte Common Antigens

Share to Leukocytes

Share to Neutrophil Infiltration

Share to Neutrophils

Source

Open in PubMed Open full text

Identifiers

PMID: 28465358
DOI: 10.1101/gad.294991.116
PMCID: PMC5435890

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant IDH1 regulates the tumor-associated immune system in gliomas.PMID 28465358Read ↗

Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers.Semantic proximity Read ↗

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomasSemantic proximity Read ↗

The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in GliomasSemantic proximity Read ↗

Implications of IDH mutations on immunotherapeutic strategies for malignant glioma.Semantic proximity Read ↗

Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in miceSemantic proximity Read ↗

Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma.Semantic proximity Read ↗

IDH1 Mutant Glioma Favors Group 3 Innate Lymphoid Cells and Is Resistant to Immune Checkpoint Expression.Semantic proximity Read ↗

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.Semantic proximity Read ↗

Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma.Semantic proximity Read ↗

Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.Semantic proximity Read ↗

ISG20 promotes local tumor immunity and contributes to poor survival in human gliomaSemantic proximity Read ↗

The R132H mutation in IDH 1 promotes the recruitment of NK cells through CX 3 CL 1/ CX 3 CR 1 chemotaxis and is correlated with a better prognosis in gliomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.